Skip to main content

Table 2 Correlation between CYP26A1 expression and the clinicopathological variables in head and neck squamous cell carcinoma patients via tissue microarray analysis

From: Increased expression of the retinoic acid-metabolizing enzyme CYP26A1 during the progression of cervical squamous neoplasia and head and neck cancer

   CYP26A1 expression  
Variables Cases (n) Negative (%) Positive (%) P
Age (years)     
  <60 59 31 (52.5) 28 (47.5) 0.136
  ≥60 61 41 (67.2) 20 (32.8)  
Sex     
  Male 104 61 (58.7) 43 (41.3) 0.586
  Female 16 11 (68.8) 5 (31.2)  
Primary tumor status (pT)     
  pT1 9 6 (66.7) 3 (33.3) 0.025*
  pT2 38 25 (65.8) 13 (34.2)  
  pT3 35 25 (71.4) 10 (28.6)  
  pT4 34 13 (38.2) 21 (61.8)  
Lymph node involvement (pN)     
  Absent 65 40 (61.5) 25 (38.5) 0.574
  Present 52 29 (55.8) 23 (44.2)  
Distant metastasis (M)     
  Absent 115 69 (60.0) 46 (40.0) 1.000
  Present 4 2 (50.0) 2 (50.0)  
pTNM stage     
  pStage I 7 5 (71.4) 2 (28.6) 0.015*
  pStage II 26 18 (69.2) 8 (30.8)  
  pStage III 35 26 (74.3) 9 (25.7)  
  pStage IV 49 21 (42.9) 28 (57.1)  
  1. *Significantly different by the chi-square (χ2) test.
  2. Abbreviations: CYP26A1, cytochrome P450, family 26, subfamily A, polypeptide 1; pTNM, pathological tumor-node-metastasis.